Black Diamond Therapeutics, Inc. (BDTX)
2025-06-30 | 2025-03-31 | |||
|---|---|---|---|---|
| License revenue | - | 70,000 | ||
| Research and development | 9,319 | 10,506 | ||
| General and administrative | 4,101 | 4,964 | ||
| Total operating expenses | 13,420 | 15,470 | ||
| Income (loss) from operations | -13,420 | 54,530 | ||
| Other income (expense) | 1,741 | 1,417 | ||
| Interest income | 1,118 | 595 | ||
| Total other income (expense), net | 2,859 | 2,012 | ||
| Net income (loss) | -10,561 | 56,542 | ||
| Unrealized gain (loss) on investments, net | -6 | -43 | ||
| Comprehensive income (loss) | -10,567 | 56,499 | ||
| Net income (loss) per share basic (in dollars per share) | -0.19 | 1 | ||
| Net income (loss) per share, diluted (in dollars per share) | -0.19 | 0.98 | ||
| Weighted average common shares outstanding, basic (in shares) | 56,803,450 | 56,663,798 | ||
| Weighted average common shares outstanding, diluted (in shares) | 56,803,450 | 57,673,099 | ||